Worldwide pharmaceutical sales are estimated to be more than $750 billion annually with significant opportunities for growth. Aging populations, expanded healthcare, declining R&D productivity and drug patent expirations have created increased demand for safe and effective drugs. Efforts to reduce health care costs have also heightened interest in new uses (‘indications’) for approved drugs and unique combination products using established drugs. This strategy accelerates development, reduces development costs and improves success rates because approved drugs typically have extensive human safety records.
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs selected from its extensive portfolio with the potential to be safe and effective for improving patient care. The company’s product pipeline includes new uses for approved drugs and new molecular entities (“NMEs”) for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease.
Central to the company’s successful clinical development programs are its strong relationships with clinicians, academic medical centers, regional hospitals and specialized product and service providers. A phase II clinical development program is underway in addition to sponsored basic, translational and clinical research projects aimed at specific disease mechanisms. The company has built a robust portfolio of issued patents and pending patent applications on its products.
A key strategy includes actively exploring partnership, licensing and other collaboration opportunities that will maximize the potential value of the company’s product development programs.
Learn More About:
Premature Ejaculation (PE)
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE | 2.67 |  0.14 (4.98%) |
Ampio News
05/14/2012 | Press Release
Ampio Pharmaceuticals Schedules 2012 Update Webcast
05/11/2012 | Press Release
04/30/2012 | Press Release